Table 2.
Overview of peptide inhibitors explored as drug candidates and described in this review.
| Target System (PDB Code) | Region Being Mimicked (Residue Range) | Peptide Sequence | % Inhibition |
|---|---|---|---|
| MoxXT (MazEF) from B. anthracis (using structural homolog 1UB4) | Putative α2 helix of the toxin MazF (55–62) | KAELVNDI | 22 |
| Putative C-terminal toxin-binding region of the antitoxin MazE (66–73) | NLHRNIW | 20 | |
| VapBC30 from M. tuberculosis (4XGQ) | α1 helical region of the antitoxin VapB30 (52–59) | ELAAIRHR | 43 |
| α2 helix of the toxin VapC30 (14–30) | DEPDAERFEAAVEADHI | 53 | |
| α4 helical region of the toxin VapC30 (48-56) | RFGEPGGRE | 73 | |
| VapBC26 from M. tuberculosis (5X3T) | α4 helix of the toxin VapC26 (54–65) | DAELAVLRELAG | 82 |
| HicBA from S. pneumoniae (5YRZ) | α2 helix of the toxinHicA (53-67) | ELNKYTERGIRKQAG | 80 |
* 4HKE was used to refine the peptidomimetics based on MoxXT.